Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound 5, or 2-(naphthalen-1-yl-oxalyl-amino)-benzoic acid, is a synthetic organic small molecule belonging to the class of acylaminobenzoic acids and derivatives[1][3]. It has been studied as an experimental compound with potential therapeutic applications but is not approved for any indication. Its precise mechanism of action and primary pharmacological targets have not been established in the literature. The compound has a molecular formula of C19H13NO5 and a molecular weight of approximately 335.3 g/mol[2]. There are no known clinical trials beyond preclinical or early experimental phases, and it is not currently marketed as a pharmaceutical product[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound 5, 2-(naphthalen-1-yl-oxalyl-amino)-benzoicacid.